EMAGLIFLOZIN L 25/5MG

EMAGLIFLOZIN L 25/5MG is a powerful combination of Empagliflozin 25 mg and Linagliptin 5 mg, designed to provide advanced dual-action therapy for adults with Type 2 Diabetes Mellitus (T2DM).

Empagliflozin (an SGLT2 inhibitor) lowers blood sugar by helping the kidneys remove excess glucose through urine, while Linagliptin (a DPP-4 inhibitor) increases incretin levels to boost insulin secretion and reduce glucose production. Together, this combination helps patients achieve better glycemic control, supports weight management, and provides additional heart and kidney health benefits.

✅ Key Benefits:

• Dual mechanism for effective blood sugar control

• Reduces the risk of heart-related complications

• May aid in weight management and lower blood pressure

• Convenient once-daily dose

• Low risk of hypoglycemia when used as directed